HealthTech Innovation Days

October 5&6 2020 at the Peninsula Paris and virtually





+780 Registered participants
+150 Selected European Healthtech companies
+300 Investors from all around the world
+1000 Private meetings
+15 Pharmaceutical groups
19 Conferences with experts and KOLs

Organized by

HealthTech For Care

eit Health

EIT Health is supported by the EIT, a body of the European Union


Table of Contents

HTID GRAND OPENING

Maryvonne Hiance
President of HealthTech For Care

"For the second consecutive year, we were honoured by the support of the French President, who sent strong and encouraging messages to the entire healthtech ecosystem in his opening speech. This year, we have given a great opening to Europe by signing a structuring partnership with EIT Health and by welcoming European companies and investors (with more than half coming from outside of Europe).

Once again, HTID was able to bring together world-renowned speakers and experts to reflect on key topics related to the challenges of tomorrow's medicine, and to engender strong institutional support."

Emmanuel Macron
French President

"I am very pleased to introduce these HealthTech Innovation Days and, I want to start by thanking you all for setting up and maintaining this event ... it confirms the interest you all have in the French healthtech ecosystem. A lot has changed in the past three years, with modernized France, improved funding, simplified processes ... but big changes are in front of us.
The COVID-19 crisis revealed our strong dependence on other countries for many medical products ... efforts on re-location are necessary but I believe they are insufficient for our ecosystem. France remains a medium size ecosystem and we know we can do much better ... the key to a powerful health system is innovation ... Today my ambition is how do we make France a world leader in health technology by 2030! The first European country for the production of new medicines! How do we make France the next Boston in a nutshell!
To do this we are working on, first research, ... second financing innovation on bioproduction and digital health ... third simplicity and visibility, starting in 2021 we will significantly simplify the temporary utilization process for medicines and medical devices ... fourth access to tent ... and fifth none of this can be done by France alone we need the European market to open up! We need to invent new mechanisms such as the European BARDA ... this is crucial to keep transforming Europe.
The time will come for recovery, France needs to become the place where companies and products are invented, produced and brought to international markets.
This is our strategy, our willingness and for that I am counting on you"

Thierry Breton
Commissioner at European Commission, Internal Market

"In the recent months, the coronavirus pandemic has taken a huge toll on human life causing a dramatic impact on our economy and putting health and social systems across Europe under unprecedented pressure. The economic impact on our industry has been mixed ... some companies had to increase their production to respond to the surge in demand of top priority products ...in other cases demand dropped ... however, we have also witnessed an acceleration of the development of new medical technologies based on cutting edge discovery.
The pandemic has prompted a renewed urgency in unlocking the potential of digital tools in the health sector and in accelerating the digital transformation of health care. Digital has a key role to play here ..."

Nicolas Dufourcq
CEO of **Bpifrance**

"The past six months were quite a challenge, with the PGE, whose guarantee is managed by Bpifrance, the state, the banks and Bpifrance have contributed to supplying the French economy with 120 G€ of liquidity On top of that we had some sectorial priorities , the industry the health sector was identified, pinpointed notably in the massive subsidy program ... for a multi-billion program.
On Monday October 12, with the Minister of Health I will launch the digital health plan for France in which Bpifrance is involved. Last year we financed 450 projects in the biotech field for total of 150 million euros ... and at the same time, we invested 85 million euros in equity in biotech start-ups ... and it will not change in 2020 ... we do not want to stop!
On top of that, we decided this year an allocation of resources dedicated to research on COVID-19. ... 80 million euros on collaboration projects for clinical development of drugs and vaccines ... and 120 million euros to finance projects to increase industrial capacities.
We continue also to push the Deep Tech plan launched in 2019 which is a partnership with the French universities and research laboratories ... to trigger the creation by researchers of start-ups because if there is a weakness in France today it is not so much in financing ... what we still don't have enough is the real desire by researchers to create their start-up. It's working well ... there is a culture change in universities, something is happening ... In France there is a total commitment from the top to the laboratory with a sense of continuity which is essential for success and there is a bank, BPI, which is completely committed to achieve the vision."

«In 2020 we have been able to face this health crisis ... it wouldn't have been possible without digital health companies and innovation in digital health. It is one of France Biotech major project to strengthen the dialog with health authorities in France and in Europe to promote public private partnership for the benefit of patients and healthcare systems. France Biotech which has been helping to bring together companies in the Health Tech sector for more than twenty years has treated this event with patient interest in mind."

Franck Mouthon
President of
France Biotech

Official launch of the Venture Centre of Excellence programme during the HealthTech Innovation Days

EIF and EIT Health are happy to take the occasion of the annual HealthTech Innovation Days event to announce the official launch of the Venture Centre of Excellence programme. The European Commission's strong commitment of €150M to the VCoE is an important statement and a key decision.

EIF and EIT Health have been working for several years to shape the VCoE, a first-in kind pan-European programme designed to concretely bolster the European Life Sciences ecosystem by connecting diverse investor types in an exclusive, pan-European deal flow sharing community.

The reasons for launching this Venture Centre of Excellence programme at the HealthTech Innovation Days in partnership with HealthTech For Care, are threefold:

- First, the event gathers together investors from across the international ecosystem
- Second, the Région Ile De France has provided strong financial support to install the EIT Health VCoE operational team here in Paris.
- And, as we have heard from the previous leaders in this session, cooperation is increasingly key to delivering concrete results.

The VCoE is expected to boost Europe's innovative life science ecosystem, support breakthrough technologies, ensure products and services are commercialised and scaled in Europe, and help attract talent and innovation from beyond our borders. To do so, programme members will be able to use a suite of Artificial Intelligence tools developed by Skopai, a spin-off from the University of Grenoble, in order to amplify their scouting, sourcing and syndication operations. The custom-built AI platform will allow creation of syndication scenarios of start-ups that are of interest for members, based on confidentially-set parameters. The VCoE programme is a unique and concrete response to the goals and strategy outlined during the Opening session of HTID, namely by:

- Providing new support mechanisms for the European Life Science ecosystem.
- Leveraging private investor capital thanks to the strong financial support from the European Commission in order to deliver real, market-based impact to Europe's best Life Science innovators.
- Promoting European sovereignty in a key strategic domain, in this current COVID-19 context and beyond.
- Combining regional, national, and European support to deliver concrete market-based solutions.
- Aligning European bodies, by breaking down silos.
- Creating public-private partnerships to impact the market, designed and conceived in a bottom-up manner ... thanks to our partners that have been instrumental in making it happen, even if... it doesn't mean that they will subscribe at the end

The programme's goal is to have a maximum of 20 Venture Capital fund managers selected alongside a maximum of 20 to 30 industrial, TTO, and health insurance members to produce 2 billion euros of economic impact over the coming 15 years.

Jean-Marc Bourez
Managing Director,
EIT Health France & Head of the VCoE

"I am happy to announce that the European Commission is committing an anchor investment of €150M to the Venture Centre of Excellence, co-developed by EIT Health and the EIF. It is a first of its kind, open innovation platform in the Life Science sector in Europe." **Thierry Breton, Commissioner at European Commission, Internal Market.**

«HTID 2 was for us a great opportunity to promote formidable science and technologies, and to attract worldwide investors who were able to witness the incredible energy and potential of our strong European HealthTech industry. All this ecosystem working towards a single goal : bring better care to patients all around the world. We are convinced that HTID 3 will make no exception.» **BDC Sciences**

Alexandra Dublanche
Vice-President of the Ile-de-France Region

"With Valérie Pécresse, President of the Ile-de-France Region, we were determined to do everything in our power to [bring] this amazing 15-year (...) programme [co-developed] by EIT Health and the European Investment Fund to Paris. We offered a €2m subsidy to start VCoE activities in Paris Region (...). Considering the world class networks of both EIT Health and EIF, I am confident that the VCoE will become a game changer for the European Health and Life Science innovation landscape.

Why EIT Health partnered with HealthTech for Care to organize the HealthTech Innovation Days ?

The main reason why we decided to partner together is due to the makeup of our respective communities. EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations – industry, pharma, health insurance funds, healthcare providers, incubators, investors –, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. In this way, EIT Health is a sort of "MIT-like" body, interconnected with European governments.

We are intentionally spread across different geographic nodes, called "Co-location Centres". To give you a concrete example, in France we are represented by various partners in two major regions, Île-de-France and Auvergne-Rhône-Alpes, which together represent more than 75% of private and public investments made in R&D and life sciences in the country.

We have seven Co-location Centres throughout Europe. France is an autonomous Co-location Centre. Others, on the contrary, group together several countries such as the Netherlands, Belgium, Luxembourg and Israel, brought together in a Co-location Centre headquartered in Rotterdam. Another groups Scandinavian countries including Latvia and Estonia, with its head office in Stockholm and facilities in Copenhagen. Germany, Austria and Switzerland are covered by offices based in Manheim and Heidelberg. Spain is an independent Co-location Centre headquartered in Barcelona with a satellite office in Madrid. In 2021 the management of our UK and Irish partners will shift from London to Dublin. Finally, Central European countries members of the EU are brought together thanks to specific healthcare innovation support through our InnoStars office headquartered in Budapest and with a satellite in Warsaw. All these Co-location Centres are interconnected to ensure that our activities cover the entire health innovation value chain.

We conduct annual Calls for Expressions of Interest and additional projects within our own organisations. We finance our project portfolio alongside our partners, through grants.

In fact, EIT Health bases its activities on the concept of "Knowledge Triangle", the meeting point between business, research and education. We support our partners in their development of new technologies for therapeutics and biotechnology, MedTech, digital health, and solutions based on artificial intelligence. We finance these innovative projects over a period of three years, or, depending on the innovation's time-to-market, up to five years. EIT Health is one of the Knowledge Innovation Communities supported by the European Commission.

The reason behind our decision to partner with HealthTech for Care to organise the HealthTech Innovation Days is that, in a very similar way, we regroup and coordinate relationships within our the field: trusting relationships shaping collaboration between the different types of actors of the healthcare innovation value chain.

EIT Health brings its European network to HealthTech For Care's activities. We were already involved in the first edition of HTID which took place in 2019. HTD is already one of the main events in the Life Science field. We decided to partner with Health Tech For Care to establish a long-term strategic collaboration, and make HTID a key and renowned event at the European level, welcoming investors from different backgrounds, such as fund managers, equity fund managers and corporate venture capital funds.

eit Health — EIT Health is supported by the EIT, a body of the European Union

HealthTech For Care

Ms Agnes Pannier-Runacher,
Minister Delegate to the Minister of the Economy, Finance and Recovery, in charge of Industry

"This event is very important to foster collaboration within Europe and healthcare and the innovation ecosystem ... and this sector is a top priority. We want to help Health Tech companies from the development of their innovations to the go to market ... our aim is to boost attractiveness of France as a pharma hub. The waiting time for patient access to new medicines has been reduced but we need to go further again.
Mind is changing, culture is changing.
In our national recovery plan our top priority for Health Tech sector is to stimulate innovation, development and production."

«Financière Arbevel is committed to support and finance the European disruptive technologies and companies through various vehicles (Pluvalca Disruptive Opportunities, Arbevel Life Sciences Crossover I, ..). It is our role to sponsor world-class events such as HTID 1 & 2 and we are further committed to HTID 3. Financière Arbevel is and will be instrumental in showcasing the fantastic European innovation capacities in health.» **Marc Le Bozec, Fund Manager at Financière Arbevel**

COVID-19 : Financing, challenges & healthtech ecosystem

Economic impact of Covid-19 on the healthtech ecosystem

Christian Pierret, **Former French Minister of Industry**
«All over the world sufficient money to finance what we are»

Well, this event takes place in a very important moment of the economic world life. That's to say at the moment where the COVID-19 raises deep and difficult questions about the future of the economy, the conditions of growth, and what is to do to remain optimistic and to remain proactive in this world economy.

We, who know the kind of upheaval and the risks in terms of job destruction, of growth, of development and of equality between the different countries of the world, have chosen to give a demonstration that it is possible to be confident in the future.
And this confidence is based on two main issues.
The first is that here everything that is said and done is aimed at the development of investment and R&D. And we know that new growth for decades to come will be based on innovation and more investment than in the past. The first problem is therefore to say very clearly that investment is essential, that R&D is essential, that science is essential.
The second remark is that, nothing is possible without entrepreneurship, without this kind of confidence that is the resilience of the leaders of the economy and of companies. And nothing is possible without any support from local authorities. I mean the states, but I mean essentially the European Union, for instance. Regarding Europe, and international organizations, we are sure that nothing is possible if all, at the global level, we do not decide to cooperate to make efforts at the different levels such as companies, countries, states, organizations, to converge and to collaborate efficiently with each other.
So, entrepreneurship, support of public bodies and confidence, investment and research are all key. And here this sector represents probably one of the four or five domains, which are on the edge to win in this worldwide battle. There is all over the world sufficient money to finance what we are, what is at stake here and to mobilize this money, you should go through a demonstration that, confidence to go forward after the COVID-19.

And, as the philosopher said, what doesn't kill me, doesn't weaken me but reinforce my own ability to win.

Stewart Cole, President of the **Pasteur Institut in Paris**
« We need to invest more in R&D for emerging infectious diseases »

During the roundtable dedicated to the "Economic impact of Covid-19 on the Health Tech ecosystem" , I explained a little bit the history of the Pasteur Institute, how it has been active in the field of infectious disease research, immunology and global health since its beginning, and how our founder, Louis Pasteur, was a pioneer in the area of translational research, ensuring that all of his discoveries were turned into applications of benefit to humanity.

The discussion was very interesting because it addressed the impact of covid-19 on the health tech sector and discussed both the threats and the opportunities which were arising.
There were many opportunities, and in order to make the most of these opportunities, I think there are a couple of take-home messages which I would like to impart.

The first of these is that we need a more level playing field in terms of funding for translational research in Europe. Our American colleagues for many years have had extensive support from BARDA, a government agency which puts public money into what I perceive as projects of major impact in the health sector. In Europe, we do not have an equivalent agency, and I think it's time that such an agency to be created so that we could compete on level terms.

The second message that I think the most important is to do with emerging infectious diseases. And during the past 20 years, we've had three major outbreaks of coronavirus infections, the latest one being SARS coronavirus, to be responsible for covid-19, which has caused incalculable suffering, loss of life and huge economic losses.

Of course, in order to prevent such major disruption to society, to our economies and to the world moving forward, WE NEED TO INVEST MORE IN R&D FOR EMERGING INFECTIOUS DISEASES.

"A pleasure for BNP Paribas to attend the second edition of the HTID conference, which successfully offered an alternative format in the current Covid environment to meet a multitude of exciting biotech companies. We look forward to attending the third edition and deepening and enhancing our relationship with the participants".
Dr. Zahid Moneer, PhD, MBA (Cantab) Managing Director Investment Banking, Healthcare
BNP Paribas – CIB – Global Banking

Impact of Covid-19 on biotech and pharmas and financing opportunities



Facing Covid-19: challenges for Biotechs and Pharmas

Eric Falcand, Global Head of Business Development and Licensing, **Servier**

We heard in this roundtable devoted to the way Biotechs and Pharmas face the challenges of COVID-19 pandemic, which was very interesting, with different points of view from Biotechs and Pharmas and more generally from the LEEM. In fact, the COVID-19 has caused widespread disruption throughout the industry.

These disruptions have been evident in R&D, with not only delayed clinical trials, but also, as we can see, a potential impact on data integrity, especially as there has been a difference in appreciation between the United States and Europe. In Europe, a cautious approach has been adopted and studies have been stopped. In the United States, studies were not always stopped and there was an average delay of only three months in inclusions. However, we can see now that many COVID-19 patients were included in these studies, and therefore, there is bound to be an impact!

We obviously heard from speakers as well about the impacts on the supply chain. We must adjust to make sure that essential drugs will reach patients in all therapeutic domains and not only those concerned by the COVID-19.
Commercial activities have been impacted as well.

In finance, we have seen the curves; basically there has been a dip in the financing in the early days of March and April. But very quickly, May and June have been the biggest financing month ever for the industry. I think that behind all of this there's high hope and a great message of positivity, even if, obviously, the impact on the sector has been tremendous.

We discussed the impact on M&A and partnering. It's very likely that they will not be affected on the long run, even without adjustment, as there will be in fact more opportunities arising. Moreover, some companies including biotechs have the ability to execute. It will be a little more complicated in terms of transaction or due diligence but it will not slow down the trend.

I think that the most important message is mainly on the ways of working. Obviously this COVID-19 situation helps people think how to collectively operate and how to interact with other stakeholders. We have seen unprecedented collaborations between various stakeholders and especially with regulatory bodies. This is a lesson we should remember as it works, and we should obviously continue this way. We also saw that for the treatment and vaccine against COVID 19 . I mean, today everybody is in the same boat trying to find a solution.

The last point is about people. We have not heard much in this roundtable about recruitment; there have been mixed figures around that, in the sense that some companies have experienced delays in recruitment, others not. So, it varies basically depending on who you are. And, actually that's probably one of the lessons that was given by one panelist, the reality is that the good employee will be even better after this crisis, as it has really been a catalyst, and the less performing people prior to the crisis will likely be the losers. And that is probably the motto of this COVID-19 situation and certainly the conclusion of this workshop.

«The worldwide pandemic situation is a unique opportunity to rethink the way we collectively operate and collaborate between stakeholders with the need to be faster than ever in discovering and delivering innovative treatments to patients. The HTID is a great event to meet and interact with other players of the European healthcare ecosystem and we look forward to the 3rd edition in 2021.»

Eric Falcand, Vice-President Global Business Development & Licencing, Servier

Impact of Covid-19 on biotech and pharmas and financing opportunities

Impact of the Covid-19 crisis on financing opportunities and risks

Philippe Monteyne, Partner @Fund+

Let's talk first about this panel, which debated about the impact of COVID-19 for VCs businesses who invest in biotech companies. With the six people around the table, we covered a broad scope in terms of experiences, in terms of international coverage and type of investments. There were people from Sofinnova, Orbimed who are very large international funds. We had somebody from Euronext, one person from Financière Arbevel, which is more boutique based in Paris, and then Angel Santé represented the business angels.

I am myself a partner at Fund+ a recently created a fund in Belgium with more than 200 million euros in asset management and, more than 16 companies in the portfolio. And it was great to not only to share my experience, but also to compare my own experience with the experience of these different people working at the business angel level, working at larger VC level or working with Euronext.

What we all observed is that, for as far as we were concerned, we see that there is money available to invest in the world, that the COVID-19 was, of course, making things a little more complex. We had then to adapt ourselves to a different way of working, but it was not impossible, and it has been possible to make very significant investments, as we made several ourselves. Indeed at Fund+, just over the summer, we finalized three private investments. And this is of course a lot for us. What could mitigate the negative downsides as, of course, all our portfolio companies are suffering from some impact on the clinical development, on the preclinical development? There is a paradoxical situation between suffering in the execution, the operational difficulties, the operational challenges, and on the other hand the opportunities and the fact that there is money to invest in the biotech world.

So, about HTID in general, many congresses are dedicated to early stage biotech companies, startups, and then, of course, you have some events like the JP Morgan conference, which are definitely addressing the very top level and more late stage companies. HTID I think has a card to play and is playing a good card in addressing this gap. The idea to become a sort of mini JP Morgan in Europe would be really ideal !

Nissim Darvish, Partner at Orbimed

«The balance between opportunities and risks»

Let me start with what I find to be interesting and stimulating for me: I did find the lectures where an overview of current status of a specific topic like cell therapy or gene therapy was given to be of important for both investors and entrepreneurs. I wish they were more like that. Also the fact that you attracted the strategic to give their view as well as to articulate the topics and type of companies they are looking to collaborate with is benifical to the audience. The discussion following these kind of overview presentations was also intersing and educational.

The involvement and the participation of the strategic in the conference and these kind of panel discussion are of importance and will attract more audience to the conference. It was interesting to listen to these guys. So I think that was number one of interest for me. Number two in my list was the 1X1 meetings ,even though they were all virtual meetings. I think I took more than 20 meetings during the conference, and even more after the conference itself as the time was limited. For the investors this is a great tool to follow up with companies and get introduced to new ideas. I was back to back meetings with both other VC investors and ventures both early and at more advanced stages. This is a great platform to meet companies from all over Europe investors but that gave me a good feeling of what is going on in Europe .

As for the financial/investors/VC panel, I did not find it of real beneficial, and I must admit that I did participate at such panel at the HTID. If such a panel will be run again, the topics of discussion should be around what are the hot topics for the VC now adays, what make companies attractive, discuss the difference between USA and EU landscape, what are the gaps; Management, financials ect.

All in all HTID is a great platform that can become on of leading conferences for the healthcare industry in Europe.

«This new edition of HTID has been once again a great success showing how important it is to strengthen relationships between all stakeholders in the health environment- Pharmaceutical companies were proud to participate to such initiative and support the upcoming editions!»

Leem, Les entreprises du médicament

HEALTH INNOVATION IN EUROPE : Assets

Cellular therapy & gene therapy: where do we stand, what perspectives?

Pr Fabrice Andre, Head of Research,
Gustave Roussy Institute, Villejuif

«And the last thing which I think sums up the whole debate is this slogan used by one of the speakers: RECODE FOR LIFE.»

We just had a very good session dedicated to gene therapy and cell therapy which cover a very wide area of diseases.

What conclusions can we draw from it?
From a scientific perspective we have seen that it is possible to replace genes, and this led to major advances and major improvements in some patients, mostly with very rare diseases.
Regarding cell therapy, its effectiveness is already demonstrated at least in the field of immune deficiencies and blood malignancies even if they are still problems mainly related to T cell persistence, secondary resistance and toxicity.

What are now the main issues that we must address in order to extend the development of these innovative approaches and to have a real societal impact?
The first, and it was debated among the speakers because there was no consensus on this point, concerns the optimal regulatory path to make these new therapies available. The problem here is that if we have to develop and register a new drug for each gene, the number of genes to be replaced is far too high and it becomes unrealistic. While we all agree that safety is a key issue and we cannot compromise on it, at the same time we need to find new regulatory approaches for these products to facilitate their development and accelerate their approval.

The second point raised was the issue of scaling and manufacturing. And here there was also no consensus on the solutions, but new technologies or improvements of existing technologies should make easier the manufacturing and expand patient access.
The third point is the patient access to these innovative therapies. There was a general consensus here that access is still very limited, more than it is for targeted therapies or antibodies. There is therefore a major problem of moving from a system where only a few patients will have access to the medication they need. Some of the speakers pointed out that there are new ways to invest, between philanthropy and pure profit. Perhaps that could be a way forward.

Finally, the fourth point concerned the fact that these are biotechnology products. They have to be improved step by step and each time we make a small step it is not possible to repeat the whole assessment again. It is therefore preferable to develop a series of improvements and evaluate the whole. Perhaps we should assess whether a product that includes many knock-out or knock-in genes improves the outcome, rather than assessing the value of each KI/KO gene.

We were also impressed by the vitality and willingness of academic centers to create start-up. We have found at least four good illustrations of how a university center can be at the origin of a successful start-up that will feed larger pharmaceutical companies. And this is extremely important for the university institution.
Finally, we discussed strategic decisions. What are the criteria for deciding gene replacement? Why replacing a gene instead of trying to design a drug? This question has arisen about the modulation of the epigenetics of the SUV39H1 protein, why turn it off using cell therapy if it can be targeted by a drug? Another question that could be a limitation to this approach concerns the modification of the immune response when we replace a gene. This is a real problem.

And the last thing which I think sums up the whole debate is this slogan used by one of the speakers: RECODE FOR LIFE.

Frederic Revah, CEO, **Genethon**

«Gene therapy is living a thrilling period.»

Gene therapy is going through thrilling times.
We see numerous compounds reaching the market, both for rare genetic diseases and for cancer indications. And, as those products develop and as tens of products are at Phase 3 development stage, the challenge for the future is ensure sustainable flow of drugs reaching the market by addressing the specific issues and challenges gene therapy faces. Of course, success is strongly dependent upon excellent science, on excellent understanding of the molecular bases of the diseases we're addressing, but beyond this science and beyond this translational medicine, we really have to address some key hurdles that might be limiting factors in the future.

What are these key factors?
If we want to make these gene therapy products available for a large number of indications and a very large number of patients, we certainly have to solve the question of Bio-production.

Of course Bioproduction for gene therapy raises industrial and logistics issues such as for instance in ex vivo modalities as CAR-T treatments. But not only, for in vivo gene therapy modalities the quantities of virus that you have to produce is such that existing capacities will not be able to match the needs; even for rare genetic diseases such as Duchenne muscular dystrophy, which requires all muscles from the body to be transduced. Here, you know, you have to keep in mind that whereas for a vaccine you need 10E6 viral particles per dose, for Duchenne muscular dystrophy, you need 10E16 viral particles per dose! Here you have to come up with strong improvements, disruptive improvements in production process.

You will not have the possibility of doing more with the same process, but you actually need to come up with new and disruptive technologies, new approaches in bio-manufacturing. And this is going to be a key element among the number of factors what will be required to also decrease the price per unit.

Then there's other elements that have to be worked out, improving efficiency of the vectors being more efficient, better expression cassettes, which also will contribute in decreasing the doses to be injected.
An additional key aspect for future development for gene therapy is really addressing the possibility of reinjecting those products. We are treating today patients only once with spectacular results

«Sanofi and HealthTech Innovation Days are both involved in improving patient access to health innovation. It was a pleasure to be here for the second year in a row.» **Sanofi**



Frederic Revah, Following interview

over several years. But, as the patients grow old they might need to be redosed and we will have to transform, what is today a one-shot treatment into a repeated treatment or maybe even a chronic treatment. And to achieve this we have to be able to overcome the immune response following injections and develop immune modulators, which will allow us to address this issue.

Our industry has to face the question of pricing in order to ensure wide patient access to these therapies. For the time being, gene therapy products are the most expensive treatments on the market. Can this be a sustainably the case? I don't think so. If we successfully cope the challenges I mentioned before I consider that we can bring those products to a more accessible pharmaco-economic equation.

Winning together: Successful corporate, healthtech companies and academic collaborations
Dominique Costantini, Chairman and Director of early development, **OSE Immunotherapeutics**



Building relationships with academic institutions is of major importance for Biotechs and collaboration takes place at different levels.

First of all, at the clinical level, because it is the beginning of any discussion. To understand what kind of unmet need we could solve with our product, we at OSE Immunotherapeutics have antibodies that targets immune checkpoints expressed in the myeloid lineage, the first meeting obviously had to be about clinical orientation.

But behind that, we have also implemented a research approach with bioinformatic tools, with artificial intelligence in order to anticipate and explore different levels of interest from the new targets on which we are working. This is the reason why we have worked in depth with Leon Berard anticancer center. Jean Yves Blay, director of the center, has a formidable team around him. It was a key element getting the whole team involved and allowing our colleagues to have in front of them people experienced in the field of immune escape.

To understand, if the target expression changes, and, this is very interesting, if we are not in the presence of something completely different in theory. But also to understand the clinical situation, what is our vision of this target and the type of modification to better understand the future. The last point is to understand what rare cancers really are. A certain time for development is very important and these discussions on rare cancers are also important to understand if the product could also benefit from this possibility of exploring rare cancers and thus accelerating its development, it is an key element to our operational and development processes.

So, what are really the main factors that drive the relationship and the success of the partnership? I think what is essential is team collaboration. This means that when we have Jean Yves Blay who is able to work with people who have a different vision, that is the key. And that vision is very important when we have a research team, a bioinformatics team, a translational team, and obviously a clinical team, then we have a continuum of people to who are dedicated. Then our team of researchers and clinicians can have access to a whole discussion process and not a step by step one. It is really a general process. And I think that is very important for the type of collaboration we have and which is exceptional!

« Invest Securities, part of All Invest group, is very proud to be the Investment bank partner of the HTID and to have contributed to the 2020 edition. Our support to the HTID is for us a major rendez-vous in all our contributions to the European Biotech and Medtech sector. All the healthcare team, including financial analysts, investment bankers and sales team will continue to support this great event and all the industry." **Invest Securities**

HEALTH INNOVATION IN EUROPE : Opportunities

Opportunities and challenges for Innovative Healthtech companies in Europe (Bio-Deutschland & France Biotech)

Oliver Schacht
PhD, Bio Deutschland
President

«FRANCE AND GERMANY BEING THE TWO EU KEY ENGINES, WE NEED TO COME TOGETHER TO DEVELOP OUR BIOTECH INDUSTRIES»

The recent HTID conference was an excellent platform to bring together entrepreneurs, investors and stakeholders in the European biotech industry. I think one of the key aspects that emerged from the conversation was that there are very common themes on both sides of the River Rhine and frankly, all across Europe, in terms of the key challenges that especially growth companies are facing, after they've been started successfully, after they've made the first steps, when they're trying to really grow towards being able to run product development, clinical trials, scale up issues, even manufacturing capabilities.

And I think we've got some prime examples in the COVID-19 crisis that show how we can successfully address these with providing the environment and the ecosystem for funding and financing.

The theme that really emerged here is this common interest, while, of course, an entrepreneur or founder of a company will likely always look in his or her local environment and will start the company where (s)he is, where the weather is nice, where the food is good. We heard a lot about, you know, the south of France as one. Opportunistic founders in Germany will likely start there, but I think the perspective to see me as a BIO Deutschland representative here was very, very welcome. One, that is we've really got it right from the start. Look beyond national borders and think again, something that the current crisis is teaching us every day, that while, yes, you need to take local, even really small community individual measures, taking a purely national approach makes no sense at all. This is something that goes well beyond any single country. It frankly goes well beyond Europe and it's a global challenge.

But we as Europeans, in the biotech industry where France and Germany are the two key engines of the European Union as we know it today and as we'll have it after the Brexit, we need to come together to develop our biotech industries. And offering a

platform such as HTID to young and growing biotech companies in Germany to come to France, meet with investors, meet with stakeholders is definitively essential. And we've heard already some case studies and examples of even very early on joint ventures, collaborations.

I just read this morning in the news, that Evotech just got a major new financing from Qatar. But if you think about it, Evotech recently has also become a French-German company and in fact, historically, they've been German-UK. So, they're really a global organization, but with a very, very strong European and in fact French-German footprint. For me, this is a perfect example of getting the idea and planting that seed and then seeing what happens, whether it is German investors investing in French companies, French investors investing in German companies, European or US investors investing in exciting startup companies where the technology is the best. That, to me, is certainly a prime example of everything Europe should be in terms of collaboration, open platforms, communication, common goals and, getting creative and rolling up our sleeves and getting things done.

To me, that's really what Europe is all about. That's what our biotech associations are all about. And having these communication platforms is really a great opportunity of bringing people together that, when they meet, they are going to be creative with ideas will be floating around and who knows, maybe new ideas and new business opportunities from which collaborations may emerge.



«Dechert is proud to continue to support HTID and her founder and President Maryvonne Hiance on this strategic initiative for the development and success of France´s biotech and medtech sectors. The second edition of HTID was perfectly orchestrated in unprecedented conditions. This renewed success demonstrates France's central role in Europe in life sciences especially innovative areas such as e-health or AI. Dechert's Paris specialized platform composed of +30 fully dedicated lawyers is pleased to be part of HTID's history.»
Alain Decombe, Partner, Dechert

HEALTH INNOVATION IN EUROPE : Opportunities

Opportunities in setting stronger relationship between health industry & patient association

Gérard Raymond, President of **France Assos Santé**

«Why and how strengthening them?»

Today, we have reached a point where we need real political will, to truly enter digital health and include our entire health system in these tools. And it seems important to us that there be a real policy to say that this is the tool that will allow us to transform our health system and it must be done quickly.

The second thing is that, in effect, we are trying in this broad vision to no longer compartmentalize public institutions, manufacturers, start-ups, etc. Everyone in the legal framework can finally have their place, provided they respect the rules of the game. For example, on the use of anonymized health data by private actors, we must stop playing to scare ourselves. It is therefore necessary both for the State to show real political will but also for the various players on the ground to play collectively.

And the third point that seems important to me is that this common rule of the game is based on transparency and respect for all players and on an irreproachable and shared ethic.

These new challenges must bring people together rather than push them away and therefore it is for the patients that I represent important that there also be these rules of co-construction of validation first and evaluation then.

Opportunities in setting stronger relationship between health industry & patient association

health data highlights

Two observations were defined through this round table.

The first observation is that for the past 15 years, there has been no collective progress in digital technology in France. This leads to the following result: Software everywhere with no common rules.

It's Impossible to communicate on health data in a secure way. The government must take matters into its own hands. It must play its role in digital technology and health data management, it must define the rules and must also build a few basic tools to enable software to communicate well with each other.

The industrial ecosystem must be allowed to build value-added digital solutions based on the basic tools.

The second observation is that citizens do not have their own health data. We need to get the citizen into the «game». They must own their data. In order to solve this major problem, we hope that in 2022, a digital health space will open up to every citizen, allowing them to manage their own health data and the consents they wish to give.

Value base: Digital healthcare must become a tool for the general public. We must move forward collectively. Digital health is here to transform us towards the best. It can bring people together and create a dialogue between patients and healthcare professionals.

The conclusion of this round table ends with this important sentence to remember: Digital technology at the service of the citizen

"Pfizer is pleased to support the second edition of HealthTech Innovation Day (HTID), a true Innovation Hub in order to help the economic development of French and European healthtech companies to go further, faster, in the provision of innovative solutions for the benefit of patients." **Pfizer**

HEALTH INNOVATION IN EUROPE : Challenges

Why & How setting an efficient corporate governance in innovative firms to support growth ?

Cédric Moreau, Partner at **Sofinnova Partners**

«We are here to bring the right knowledge and guidance at the right time and help our companies attract the right people.»

Manufacturing challenges and step forwards in new therapies

Serge Braun, Scientific Director at **AFM Telethon**

«If we cannot produce enough, it will be useless and just a nice story, but a dead-end story»

"We were delighted to sponsor HealthTech Innovation Days conference in Paris for the second year in a row. Healthcare is global and goes beyond borders, and Europe is set to become the next hub for innovation, especially in healthcare over the next few years. This is why a meeting like HTID is so important for bringing together the most influential players in the industry. We look forward to the next edition! »

Sofinnova Partners

I am very happy to attend this second HTID event, which is for the first time a mix between physical and virtual meetings.

Healthcare is more than ever a hot topic. It is therefore the perfect timing for this conference, which was also supported by President Emmanuel Macron, who also emphasized the growing importance of the health tech industry in his opening remarks.

I just attended a panel on governance and it was very interesting to share our perspective as an investor and also to hear from human resources consultants, and the CEOs of the companies in our portfolio.

What is important from an investor's perspective is to be able to support a company in all phases of growth, to be able to anticipate and also coach the teams, and to ensure we have the right people, both at the management and board levels. Carrying out a Phase 3 clinical trial, marketing a product, or even entering into the clinic, requires different sets of expertise.

An early investor may not have the same expertise as a late stage investor. So, as a later-stage investor, we try to bring a specific perspective to leverage the potential of our companies. We need more of this in our ecosystem.

Perhaps in the past we have somewhat underestimated the importance of having good corporate governance in the companies in our portfolio. We are here to bring the right knowledge and guidance at the right time and help our companies attract the right people. So, we bring our extensive network and our relationships to help do this.

We are shareholders but we are active shareholders. Bringing in cash is important for sure. But we also leverage our network and help our businesses grow and take an active role. Just putting in the money and being a sleeping shoulder is absolutely not what we intend to do.

The point I made during this round table was all about gene therapy.
The question is: are production protocols and facilities enough around the globe to meet the needs? and the answer is definitively, NO.

There is a shortage of very robust production processes. This is a real threat for the whole field : we have a nice technology, but if we cannot produce enough, it will be useless, and just a nice story, but a dead-end story. And we know that there are some studies stating that, for instance, we would need something like fifteen hundreds of 2,000 liters fermenters bioreactors to produce the amounts that are needed for the current products or those that will be on the market in the coming three to four years.

The goal is to increase production yields by a factor of at least a hundred, if not a thousand in order to solve the issue. It's the conjunction of different disciplines, different areas as for instance, virology, because in most of the systems, the vectors used to transfer genes are products based on viruses, genetically modified viruses, and therefore we need to improve the knowledge of those viruses. It's also a question of cell biology, how the cells interact with viruses in order to make sure that the cells that are used to produce viruses produce larger amounts of viruses. It's a question of purification technology. It's a question of in-process control.

And we would then tackle another issue that is related to the production one. That is the cost of those products. Currently, gene therapy products are very expensive. For example, there is one product that is on the market for a rare disease, the spinal muscular atrophy, it's a one-shot administration but it costs two point one million dollars.

It's supposed to be the most expensive drug in the world and, in my estimation, is that half of its price is explained by production costs.
By improving production means, we should technically be able to reduce the costs and therefore the price of the drug. And because this may also impact patient access it's another important aspect to take into account.

Contribution of Medtechs and Artificial Intelligence to future innovations

New EU regulations in the Medtech Sector

Gary Slack, Senior Vice President Global Medical Devices at **BSI**

«The biggest change since 30 years ... think early and don't leave it too late !»

The Medical Device regulation and the IVD regulation are significant changes in European regulation. It's the biggest change since the original medical device directive in 1993. Realistically, what I would suggest to manufacturers is be aware the implementation date of May 2021 is very close. Whilst there's a transition period to 2024, if manufacturers leave it until, 2022 or 2023 to apply, I think they run a significant risk of running into problems in terms of timing, as the capacity within the European notified body system is challenged. So, I would say think early and don't leave it too late, leaving it to 2023 or early 2024 would be a huge risk for a manufacturer. And they could lose access to European markets.
The second area I would focus on is ensure you open discussions and engage your notified body as early as possible. I think the more we communicate at this point the better, as we (NB's) are still learning about the new regulations, as are manufacturers.

Probably the single biggest difference between the MDR and the previous medical device directive is a much greater focus on the post-market elements of devices once in the marketplace. And a key element of that, for example, is the Clinical Evaluation Assessment Report, which is a vital module in your technical documentation submission. Make sure you've got that right. Make sure it's complete. There is some very useful guidance in terms of templates aimed at notified bodies which can help you the manufacturer on the MDCG website. I would thoroughly recommend manufacturers look at these because they provide a very good framework and checklist.

I think I mentioned in my presentation last week, the top areas where we see potential issues in the early submissions we have received. The first by far the most common one is in the Clinical Evaluation Assessment Report (CEAR) arena this requires having a clear post market clinical follow-up (PMCF) element to your documentation submission and make sure its complete. Ensure It covers the full lifetime of the device, that it also reflects all the information that you have. If you're pointing to specific information to support that clinical data, where exactly is it? How do we get to reference data in the right place in your technical documentation? Those are areas that we're really struggling with.
Manufacturers also need to be aware of the requirements for the Periodic Safety Update Reports that we're going to be required 12 months after certificates are issued.

We (BSI) are now going to introduce a completeness check at the front end of the conformity assessment process. So, we can go through and do a relatively topline review, of what's within your technical documentation and see if there's any obvious omissions or gaps with a view that we can flag up front and prevent wasted time when we come and talk to you a few weeks /month later. For example, you don't have a complete PMCF plan. Whilst the differences in clinical requirements from MDD Revision 4 and the MDR are not much as some manufacturers think many manufacturers are still struggling to get to grips with the MDD Revision 4. If you're claiming new or expanded indication(s) for use, make it very obvious in your documentation how we can validate that claim. This will make the review process much more efficient for the notified body, hopefully shorten the review process and get your products to market.

Unleashing the true value potential of AI in healthcare, together

David Dellamonica, VP Value-based health & Innovation lead Europe at **Amgen**

The HTID conference through a great panel discussion of experts discussed the potential of AI to transform how care is delivered. Take away:
Focus on clear unmet medical needs : AI can support improvements in care outcomes, patient experience and access to healthcare services.
Focus on outcomes: Value=(outcome + patient experiences)/(direct cost + indirect cost) : AI can increase productivity and the efficiency of care delivery and allowing healthcare systems to provide more and better care to a greater number of people.

Partner with the ecosystem : AI can help improve the experience of healthcare practitioners. We talk about "Augmented physician", enabling them to spend more time in direct patient care and reducing burnout.
Put the patient at the center : AI can support faster delivery of care, mainly by accelerating diagnosis time, and help healthcare systems manage population health more proactively, allocating resources to where they can have the largest impact.

Finally, Work on challenges: data interoperability, regulatory framework, financing, reimbursement, IT infrastructure, talent management, improve acceptability by education.

«Euronext, the first pan-European listing venue for Life Sciences companies, is naturally partnering with France Biotech and HealthTech For Care to promote the innovative Healthtech sector and its financing. This successful second edition of HTID allowed us to come back on the recent developments of capital markets impacted by COVID-19 and was a great opportunity to share insights with specialized investors.»

Camille Leca, Euronext Chief Operating Officer Listing and Head of Listing France

Contribution of Medtechs and Artificial Intelligence to future innovations

Unleashing the true value potential of AI in healthcare, together

Frederic Jean & Mathieu Grajoszex (Digital Medical Hub-APHP)

«Uniting for the digital health of tomorrow»



Supporting academic researchers, developers and Medtech startups to help them on a daily basis is the objective for which the Digital Medical Hub of the Assistance Publique Hôpitaux de Paris (DMH-APHP) was created. From the technological proof of concept to the clinical validation and the medical interest of your product, DMH-APHP offers the opportunity to reassure, prove and seduce investors, partners, users and future customers with the largest European hospital as an ally.

One of the first ambitions of this platform was to bring everyone together around the table in order to be able to support products that meet everyone's needs and demands on inputs and which go up to the business model, on contributions to win-win, pay-for-performance, etc. It was a concrete action to de-risk the establishment of these products, both because they respond more precisely to the hospital demands and also to the creation of value, and by its implantation, to share both risk and value creation since the hospital was also taking a risk in the absence of standard milestones around the evaluation and the market access issues of these medtech products.
We have seen a lot of start-ups with projects coming to us with great technology but not adapted to the real hospital needs. It is like if a pharmaceutical company with a molecule under development was coming to a medical expert with convincing tests on pigs, asking him for a specific opinion in humans. It's not sufficient. We must go beyond the simple technological validations, for example, for an AI diagnostic product, simply demonstrating the specificity and sensitivity of its new diagnostic process is not sufficient.
So, intrinsic technological product performance skills are no longer sufficient in an industrial and scientific context based on what is called medical proof. And for that, you have to make some efforts. We have to look deeply for what the product gives off as advantages, whether clinical, medico-economic, economic in a local system like the hospital or a global medico-economic, in a regulatory system and a global organizational health system.

We have to look for that because the hospital buyers are extremely sensitive to these things. What is the organizational constraint of implantation?, are we going to participate in a well-being in the hospital? in its most important activities? am I convinced of the proposition value?. We are working with several companies on fairly innovative methodologies at this level to search precisely the global added value with the tool versus without the tool. Do we feel better when we feel secure?, do we feel better supported with than without? Do I have an optimized process? Am I more efficient ? faster ? more effective? financially and in my practices? You have to go that far to work on the product value proposition. If we have become something like a pure player, it is by dint of working on the value proposition of products as deeply as possible in order to de-risk their integration. That hospital buyers finally take the step and say yes, it is useful, it seems interesting for my hospital for my activities, I will acquire it and we will also work behind on business models that share the value to create whole economy, optimization.

So, why doing a spin-off of this APHP academic platform? In large part because we need to shine effectively, to be as flexible as possible, to sign or to work with people whom the public hospital is not necessarily used to working with and with whom we have to work with, the startups for example. Flexibility is also on wages, hiring. Everything that cannot be done easily and quickly in the public!
Even if you still need a strong health base to work in our area, to find all the value proposition of these tools and to be able to evaluate these, you have to be either a pharmacist or a doctor, and today we have very few resources in the public sector that offer us the possibility to find people and experts who are both doctors and who have somewhat additional skills, like engineering, business, broad, holistic vision of these subjects. And in addition, we are faced with a growing demand on the part of manufacturers, of start-ups, and of investors to de-risk their products.

And finally added to these points we have a demand increasing of the projects connected to AI. Before last summer we had about 20% of our startups accompanied that integrated what we call, a little more commonly, Augmented Intelligence. Today, more than 80% of projects integrate this Augmented Intelligence with algorithms into their system. The need for AI engineering and technician resources is exponential, it is today absent from the public hospital. However we keep a strong link with the academic platform of the dmh and this is why the Spin-off format is the most efficient way to proceed. All the academic brick is absolutely essential to be able to promote the technological solutions of our startups. So, there is a real complementarity between the two systems, which in fact can be a dimensioning and a structure quite unique both in France and in Europe. We can find similar models in the Boston ecosystem, for example.

« HealthTech Innovation Days are the perfect opportunity to meet the innovation players of today and tomorrow, to build partnerships and collaborations and to share perspectives on key trends like Artificial Intelligence. We will continue to contribute to make HTID a major and attractive event in Europe in 2021. » –

Corinne Blachier-Poisson,VP & GM Amgen France

CONCLUSION



Christian Policard (Founding Partner at Biotech Développement Conseils)

THIS YEAR HTID WAS A EUROPEAN EVENT ...
BECAUSE OF THE PARTNERSHIP WITH EIT HEALTH

The event was of a very good standard. Everything was of a very good standard, the round tables, the interventions, the speakers, etc. So, it was all on a better level than last year, especially, by the way, the roundtable on gene therapy and cell therapy. The round table on the impact of the pandemic on relationship between Pharmas and Biotechs was also very good, people were transparent and honest.

I found that this year there was a European character which was more important. For the first time, it was less, Franco-French, because of the partnership with EIT Health, because of the strong involvement of the European Commission. I found that there was a more European aspect as well, in the funds and in the Biotechs, Medtechs or artificial intelligence companies that were present. That was a strong element. I think that we really have to continue this partnership with EIT health, which has a European presence and role, both at the level of companies and more traditional financing of companies and also bringing together countries and establishing relationship between companies. I think it is very good that we are supported by the European Commission. It is also very important that there was the announcement of the creation of this European fund managed by EIT Health France and supported by the Ile de France region. These are very important elements to position the event in a European environment located in Paris.

Another point, it's good for anything virtual. A big virtual majority with relatively few people physically present, less than two hundred, could have had a very, very, negative impact. Well, but it's better than nothing, it's still not obvious but hey, it's okay. On the other hand, we did not see what we saw the first time, this kind of dynamic, dynamic and team, physical encounters, accidental, opportunism, etc. But it allowed people to participate remotely, people who surely would not have participated. Especially in the financial field, funds from the West Coast of America, or Chinese or from the Gulf funds. They would not have participated physically. And I would say that the fact that there are a lot of canceled or seriously questioned events makes people want to participate in this type of event, there was a certain appetite for the event. This made it possible to attract people. But overall, it's still much less effective than an event, like the one we experienced last year, even if there was still, from what I understood, nearly 800 people in total compared to 500 a year ago.

For each client, my company Biotech Développement Conseils (BDC) coaches, there were between 5 and 10 contacts.
I would say valuable. We are positioning ourselves towards business developpment agreements and fund raising for clinical studies, for growth in turnover, for the development of IPOs and even support for IPOs, stock market participations, refinancing .There was an event, there were positive things. I think it was good to have it.

«So, let me say that we are attempting year after year to create this good environment for life sciences, small-mid cap and big companies in Paris, in order to develop and further support these industries.»
Christian Pierret, Former French Minister of Industry

Maryvonne Hiance : President of HealthTech For Care

HealthTech Innovation Days organized by HealthTech For Care, pursues its mission of giving innovative access for every individual. This second hybrid edition of the HealthTech Innovation Days was very challenging because of the sanitary conditions. And despite that, this second event was really a great success. I can give you some figures, we had around 1,000 connections during these two and a half days of exchanges between biotech companies, investors, pharma companies etc., more than 300 global investors and around 150 selected companies, 15 pharmas among the largest ones and 19 very high level round tables. These key figures show, despite the health constraints linked to the pandemic, that the event is once again a success.
I identified three key points that I developed in my conclusions.

The very first point concerns the support of institutions.
It is unheard of to have as support the President of the Republic who, during his speech broadcast on video, was very encouraging for companies and the ecosystem. This is the first time that we have had a President of the Republic who gives such a sign of confidence to our ecosystem, he has fully understood the issues and in particular the European issue because we really need a European dimension to our activity and to our ecosystem in the field of healthcare innovation. Then come the production challenges, the digital integration challenges, the manufacturing challenges, the issues of harmonization at European level. All these points he mentioned are important for businesses. And to say that we can become a European leader, it's also the will of HTID and that is why I was touched by its message full of conviction and sincerity.
We got also a strong message from Thierry Breton, the European Commissioner, who is consistent and in harmony with our openness at the European level.
At the end, the intervention of the Minister of Industry, Agnès Pannier-Runacher, who spent a lot of time with us and who reinforced the confidence that President Macron has brought us.
And then, other personalities came to support us such as Nicolas Dufourcq, the Managing Director of Bpifrance, who for the first time came for this type of event.
All this official environment seems extremely important to me, it shows that now, we are really visible at national and European level with institutions.

The second point concerns the very high quality of the speakers and the round tables, which was unanimous. Everyone present and those who were connected confirmed it. There has been a choice of very high-level speakers who add a lot to our whole ecosystem. Once again, thanks to them and to the companies present, all the key issues that arise, scientific, economic and manufacturing, have been covered. We had speakers like Philippe Aghion, Professor at the Collège de France and the London School of Economics, and also American speakers such as Gabriela Apiou, Director of Strategic Alliances at the Massachusetts General Research Institute and Assistant Professor at Harvard Medical School.
In addition, there was enthusiasm to participate, we were extremely positive and for the first time we had a round table with patient associations in order to integrate them into the vision of HealthTech For Care to ensure that innovative health technologies and health innovation are accessible to all patients. And it is quite normal that patients are represented.

The third point for me is the European opening of HTID, the partnership signed between EIT Health and HealthTech For Care is important to give this European dimension to our event and to ensure that Paris becomes the European capital of health innovation.
There you have it, that's our ambition through this long-term partnership that we have signed with EIT Health and which, I think, will carry HTID for a long time.
Finally, the last point, it is true that I am always very sensitive to the active participation of our partners and our supporters because all were really supportive throughout the preparation of the event and I thank them very much because without them, HTID would not exist.

DESPITE THE HEALTH CONSTRAINTS LINKED TO THE PANDEMIC, THIS EVENT WAS ONCE AGAIN A SUCCESS !

Replays of the HTID round tables : https://htid-paris.streameo.fr

We are looking forward to seeing you in 2021 for HTID3

PROGRAM 2020

https://htid-paris.streameo.fr

October 5th – Salon Etoile

12:50 - 2:00 PM : Grand Opening & Venture Centre of Excellence Programme Launch

Speakers:
Jan-Philipp Beck, CEO EIT Health
Jean-Marc Bourez, Managing Director of EIT Health France and Head of the VCoE
Thierry Breton, Commissioner at European Commission, Internal Market
Hubert Cottogni, Director and Head of Mandate Management
Alexandra Dublanche, Representative of Ile-De-France Region
Nicolas Dufourcq, CEO at Bpifrance
Maryvonne Hiance, President of HealthTech For Care
Franck Mouthon, President France Biotech and CEO of Theranexus

2:00 - 3:00 PM : Keynote - Economic impact of Covid-19 on the healthtech ecosystem

Moderated by Christian Pierret, Former French Minister of Industry
Speakers :
Philippe Aghion, Professeur at Collège de France and at London School of Economics, member of Société économétrique and american academy of arts and sciences.
Jan-Philipp Beck, CEO EIT Health
Thierry Breton, Commissioner at European Commission, Internal Market
Stewart Cole, Managing Director at l'Institut Pasteur

3:15 - 4:00 PM : Winning together : Successful corportate, healthtech companies and academic collaborations

Facilitator : Paul Barrett
Speakers :
1. Donna Armentano, Executive Director External R&D Innovation and Global Head Gene Therapy at Pfizer & Jean-Philippe Combal, PharmD, Ph.D co-founder & CEO at Vivet Therapeutics
2. Pr Jean-Yves Blay, Managing Director at Centre Léon Bérard and Président of Unicancer & Dominique Costantini, Chairman and Director of early development chez OSE Immunotherapeutics
3. Amaury Martin, Director, Technology transfer and Industrial partnerships, Institut Curie. & Luigi Ravagnan, Director, Strategic Collaborations, Global Medical, Bristol Myers Squibb

4:00 - 5:00 PM : Why & How setting an efficient corporate governance in innovative firms to support growth ?

Moderated by Lilian Stern, founder of Stern IR
Speakers :
Elsy Boglioli, CEO of Bio-up
Virginie Lleu, Founder and Executive director of L3S Partnership
Cédric Moreau, Partner at Sofinnova Partners
Nawal Ouzren, CEO of Sensorion

5:30 - 6:30 PM : Impact of the Covid-19 crises on financing opportunities and risks

Moderated by : Alain Pujol, Angels Santé Board member
Speakers :
Nissim Darvish, Partner Orbimed (Tel Aviv)
Marc Le Bozec, Fund Manager at Financières Arbevel
Camille Leca, Head of Listing France at Euronext
Philippe Monteyne, Partner @Fund+
Antoine Papiernik, Chairman & Managing Partner at Sofinnova Partners

6:30 - 7:00 PM : Value creation through smart partnerships. The biotech & pharma perspectives

Facilitator : Paul Barrett
Speakers :
Jean-Paul Kress, CEO at MorphoSys AG
Alban De La Sablière, SVP Global Head of Sanofi Partnering.

7:15 PM : Cocktail Reception

Agnès Pannier-Runacher, Minister Delegate to the Minister of the Economy, Finance and Recovery, in charge of Industry

PROGRAM 2020

https://htid-paris.streameo.fr

October 5th – Salon Lobby

2:00 - 2:30 PM : New EU regulations in the Medtech sector

Moderated by Alexandre Regniault, Lawyer at Simmons & Simmons

Speakers :

Marc Julien, Co-CEO Diabeloop

Lionel Dreux, President at GMED

Stéphane Piat, Managing Director at Carmat

Gary Slack, Senior Vice President Global Medical Devices at BSI.

2:30 - 3:00 PM : Medtech - Market Access

Moderated by Samuel Levy, Founding Partner at Lauxera Capital Partners

Speakers :

Graeme Brookes, CEO at Reapplix

Whitney Cypes, Vice President Global Marketing at Allurion Technologies

3:30 - 4:30 PM : VCoE : Innovating for Innovators

Speakers :

Jean-Marc Bourez, EIT Health France Managing Director and Head of the VCoE

Rémi Charrier, Global Head of Institutional Client Relationship, European Investment Fund

Stephan Christgau, Founding Partner, Eir Ventures

VP Value-based health & Innovation lead Europe, Amgen

Marc Julien, CEO, Diabeloop

Tomasz Kozlowski, Head of Mandate and Product Development, European Investment Fund

Patric Gresko, Head of Division - Innovation and Technology Investments, European Investment Fund

Henrik Matthies, Managing Director, Health Innovation Hub (HIH) Germany

Anne Osdoit, Partner, Sofinnova Partners (MDStart Fund)

Thomas Trailov, Director Strategy & Insights | World Business Line Healthcare, Air Liquide Santé International

4:30 - 5:00 PM : Keynote on entrepreneur & VC success (Corvidia Therapeutics learning experience)

Facilitator :Paul Barrett

Speakers :

Marc de Garidel, Chief Executive Officer at Corvidia Therapeutics

Graziano Seghezzi, Managing Partner at Sofinnova Partners

5:30 - 6:30 PM : Opportunities and challenges for Innovative healthtech companies in Europe (Bio-Deustchland & France Biotech)

Moderated by

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Oliver Schacht ,PhD, Bio Deutschland Presdient

Speakers

Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP at France Biotech

Jack Elands, CEO Emergence AG

Mondher Mahjoubi, CEO Innate Pharma

Oliver Schacht ,PhD, Bio Deutschland Presdient

Jan Schmidt- Brand, CEO/CFO Heidelberg Pharma

6:30 - 7:15 PM : Opportunities in setting stronger relationship between, health industry & patient association

Speakers :

Dominique Pon, Minister Collaborator - Strategic Manager of the digital transformation in health & Managing Director of the Clinique Pasteur in Toulouse

Gérard Raymond, President of France Assos Santé

PROGRAM 2020

https://htid-paris.streameo.fr

October 6th – Salon Etoile

8:30 - 11:30 AM : Cellular therapy & gene therapy: where do we stand, what perspectives?

Moderator : Christian Policard, Founding Partner at Biotech Développement Conseils
Chairmen : Pr Fabrice André , Head of Research, Gustave Roussy Institute, Villejuif &Frederic Revah, CEO, Genethon
Speakers :
Sebastian Amignorena, Research Director at Institut Curie, CNRS
Nathalie Cartier-Lacave, Director, NeuroGenCell Brain Lab and Spine Institute (ICM), Pitie-Salpetriere Hospital, Paris
Marina Cavazzana, Head of the Biotherapy Department at Necker Hospital and Imagine Institute
Patrick Henno, Co-founder of EMERCell
Mohamad Mohty, Head of the Hematology and Cellular Therapy Department at Saint-Antoine Hospital and University Pierre & Marie Curie
Jean-Antoine Ribeil, Medical Director in Medical Affair Department at Bluebird Bio

11:30 - 12:15 PM : Renewed appetite for Medtech markets : VC/ Medtech duo

Moderated by André Michel Ballester
Speakers
Scott Bardo, Senior Healthcare Analyst at Berenberg Bank
Tim Haines, Chairman and Managing Partner at Abingworth
Sacha Loiseau, Venture Partner at Elaia
Bertin Nahum, Founder and President of Quantum Surgical

1:15 -2:30 PM : Facing Covid-19 : challenges for Biotechs and Pharmas

Moderated by Eric Falcand, Global Head of Business Development and Licensing, Servier &Christian Policard, Founding Partner at Bio Developpement Conseil (France)
Speakers :
Hugues Bultot, Co-founder and Chief Executive Officer Univercells
Christian Deleuze, Chairman of the Research & Innovation Commission at Leem
Rahim Fandi, Chief Medical Officer, Oxford Biotherapeutics
Laurent Levy, Co-founder and Chief Executive Officer Nanobiotix
Olivier Madec, Global Head of M&A and Venture Investments Servier
Frédérik Rothenburger, Managing Director at Lazard
Jacques Volckmann, Head R&D France, at Sanofi

2:45 - 3:45 PM : Manufacturing challenges and step forwards in new therapies

Facilitator : Paul Barrett
Speakers :
Serge Braun, Scientific Director at AFM Telethon
Frédéric Collet, Président at Leem (Les Entreprises du Médicament)
Richard Snyder, Vice President, Science and Technology Pharma Services, Viral Vector Services at ThermoFisher
Antoine Jourdan, Health Project Director at Direction Générale des Entreprises

4:15 - 5:30 PM : Amgen & EIT Health plenary session, Unleashing the true potential of AI in healthcare, together

Facilitator : Paul Barrett
Speakers :
Jean-Marc Bourez, Managing Director & Head of the VCoE, EIT Health France
David Dellamonica, Head Value Based Partnership & Digital innovation, DEEP AI Platform founder, Amgen Europe
Frederic Jean, Co-developer, Digital Medical Hub AP-HP
Henrik Matthies, Managing Director, Health Innovation Hub (HIH, Germany)
Philippe Menu, CMO SophiA Genetics
Karl Neuberger, Partner at Quantmetry
Arnaud Rosiers, CEO, Implicity
Stéphane Tholander, CEO & Co-Founder of Cibiltech
Stéphanie Trang, Managing Director of the AI for Health Initiative at Start-up Inside
Nicolas Villain, Director of the Research Department and AI HUB, Philips Healthcare

5:30 - 6:30 PM : Closing ceremony & Cocktail

October 6th – Salon Lobby

8:45 - 9:45 AM : VCoE : EIF Market Insights (VCoE restricted plenay)

10:15 AM - 12:15 PM : VCoE : Shaping the Member Community Vision and Discussion (VCoE restricted plenary)

1:15 - 2:15 PM : Key Collaboration and Financing Issues during the Covid-19 Pandemic

Moderator
Paul Barrett

Speakers :
Anne-Charlotte Rivière, Partner, Paris at Dechert
David Schulman, Partner, Washington D.C. at Dechert

2:45 - 3:45 PM : Behavior of stakeholders in high volatility innovative markets like HealthTech

Moderated by
Pierre Courteille, Chief Commercial Officer & Vice President Business Development at Abivax and VP France Biotech

Speakers :
Professor Randall Kroszner, Deputy Dean for Executive Programs and Norman R. Bobins Professor of Economics at University of Chicago Booth
Professor Scott Meadow, Clinical Professor of Entrepreneurship at University of Chicago Booth

4:15 - 5:30 PM : Creating a New Culture of Innovation through Collaboration: the Bridging Academia with Industry Paradigm Shift

Moderated by
Gabriela Apiou, PhD, Director of Strategic Alliances at Mass General Research Institute and Assistant Professor of Dermatology at Harvard Medical School
& Robert Tepper, MD, Partner at Third Rock Ventures and Member of the Mass General Research Institute Advisory Council.

Speakers :
Patrick Fortune, PhD, Vice President, Market Sector at Mass General Brigham Innovation Office
Saptarsi Haldar, MD, Vice President of Research and Head of Cardometabolic Discovery at Amgen
Anthony Rosenzweig, MD, Chief of the Cardiology Division at Mass General Hospital

5:30 - 6:30 PM : Closing ceremony & Cocktail

Replays of the HTID round tables : https://htid-paris.streameo.fr

About

About HealthTech For Care

The HealthTech For Care endowment fund, launched by France Biotech, is designed to support and promote access to care for all and, more specifically, to new medical technologies and drugs. The missions of the endowment fund are structured around three main areas: Supporting the development of the entire health ecosystem, accelerating the development of innovative therapies and treatments, and promoting better access to healthcare for patients in the French healthcare system and more widely throughout Europe. HealthTech For Care is administrated by Maryvonne Hiance, Elsy Boglioli, David Caumartin, Pierre Courteille, Eric Falcand, Marc Le Bozec, Cédric Moreau, Franck Mouthon, Christian Pierret and Christian Policard.

About EIT Health

Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and growing multi-morbidity are all placing pressure on health systems across Europe.
EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.
From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU.
EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.
For more information visit: www.eithealth.eu

About France Biotech

Founded in 1997, France Biotech is an independent association that brings together the country's leading innovative health companies and their expert partners. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech's mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry. France Biotech also aims to turn French innovative health technology companies into world leaders capable of designing and developing new innovations quickly and make them available and accessible to patients. France Biotech has founded and is developing the « HealthTech For Care » fund to strengthen the ability to federate, structure and encourage cooperation between the various stakeholders in the health tech sector in France and Europe. France Biotech is chaired since September 2019 by Franck Mouthon, CEO of Theranexus...

HTID 2

Replays of the HTID round tables : https://htid-paris.streameo.fr

HTID 2

Replays of the HTID round tables : https://htid-paris.streameo.fr

Thanks to our partners

Platinium

SERVIER

Super Gold

SANOFI

Gold

AMGEN INNOVATIONS
LA SCIENCE & L'HUMAIN

Bristol Myers Squibb™

leem
les entreprises du médicament

Pfizer

SOFINNOVA
PARTNERS FOR LIFE

Silver

FINANCIÈRE ARBEVEL

BNP PARIBAS
The bank for a changing world

bpifrance

INVEST SECURITIES

IPSEN
Innovation for patient care

Bronze

BDC

Dechert LLP

EURONEXT

Social Media & Contacts

LinkedIn

HealthTech Innovation Days - HTID®
https://www.linkedin.com/company/37778769/admin/

twitter

HealthTech Innovation Days - HTID®
https://twitter.com/HTID_Paris

http://www.

HealthTech Innovation Days - HTID®
www.htid-paris.com

HealthTech For Care

eit Health

EIT Health is supported by the EIT, a body of the European Union

Estelle Metzger
Project Manager Junior
estelle.metzger@htid-paris.com
+33 (0)6 38 03 80 60

Solene Goupy
Communication Manager
solene.goupy@htid-paris.com
+33 (0)6 38 03 80 19

Nathalie Donne
Projet Manager Senior
nathalie.donne@shapenlink.com
06 67 67 44 97